GT BIOPHARMA, INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
GT BIOPHARMA, INC. (GTBP) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 1.50% for the 12-month period ending 2015-12-31, per its 10-K/A filed 2018-02-28.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2018-02-28
- GT BIOPHARMA, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2015 was 1.50%, a 9.64% decline from fiscal 2014.
- GT BIOPHARMA, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2014 was 1.66%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|
| 2015-12-31 | 1.50% 10-K/A · filed 2018-02-28 |
| 2014-12-31 | 1.66% 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |